• OncoGenex Inc., of Bothell, Wash., said it plans to start a Phase II, investigator-sponsored study dubbed RANIER, to test OGX-427, a heat-shock protein 27 (Hsp27) inhibitor, in combination with Abraxane (nab-paclitaxel, Celgene Corp.) and gemcitabine in patients with previously untreated metastatic pancreatic cancer.